CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
暂无分享,去创建一个
F. Giannotti | C. van Delden | Y. Chalandon | S. Masouridi-Levrat | D. Neofytos | L. Chavaz | S. Morin | L. Royston | Anne-Claire Mamez
[1] P. Lescuyer,et al. Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients , 2022, Antimicrobial agents and chemotherapy.
[2] K. Akashi,et al. Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis , 2022, International Journal of Hematology.
[3] F. Gao,et al. Letermovir discontinuation at D+100 after Allogeneic Stem Cell Transplant is associated with increased CMV-related mortality. , 2022, Transplantation and cellular therapy.
[4] Tomoki Ito,et al. Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: A single-center retrospective analysis. , 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[5] G. Papanicolaou,et al. American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. , 2021, Transplantation and cellular therapy.
[6] C. van Delden,et al. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients , 2021, Immunity, inflammation and disease.
[7] E. Shpall,et al. Refractory and Resistant Cytomegalovirus after Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] C. van Delden,et al. Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study , 2021, Vaccines.
[9] J. Schiffer,et al. Cytomegalovirus-specific T-cell Reconstitution following Letermovir Prophylaxis after Hematopoietic Cell Transplantation. , 2021, Blood.
[10] J. Bourhis,et al. Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study , 2020, Bone Marrow Transplantation.
[11] F. Baldanti,et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[12] Ji Lin,et al. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies , 2020, Annals of Hematology.
[13] P. Hari,et al. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] N. Kröger,et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. , 2020, The Lancet. Haematology.
[15] R. Leavitt,et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[16] C. Teng,et al. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia , 2019, Transplant infectious disease : an official journal of the Transplantation Society.
[17] E. Shpall,et al. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients , 2018, The Journal of infectious diseases.
[18] Michael Boeckh,et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation , 2017, The New England journal of medicine.
[19] E. Atilla,et al. A review of infectious complications after haploidentical hematopoietic stem cell transplantations , 2017, Infection.
[20] W. Leisenring,et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. , 2002, Blood.